Oruka Therapeutics (ORKA) shares fell 6.2% in Wednesday trading even after the company said that patients in its phase 2a trial for plaque psoriasis treatment ORKA-001 continued to improve through week 28, though they stopped receiving doses after week 4.

Skin clearance rates improved by week 28, with PASI 100 responses rising to 71.4% from 63.5% at week 16, while PASI 90 rates rose to 87.3% at week 28. IGA 0/1 response rates were maintained at 84.1%, the company said.

The patients who crossed over from placebo to ORKA-001 at week 16 showed similar responses, with 40% achieving PASI 100 at week 28, while the drug maintained a favorable safety and tolerability profile, the company said.

Price: 88.70, Change: -5.85, Percent Change: -6.19

http://www.mtnewswires.com
Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.